Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-188-3 | CAS number: -
Endpoint summary
Administrative data
Description of key information
Nine studies assessed the skin sensitisation potential of terpineol multiconstituent and its major isomer alpha-terpineol. Reactions related to skin sensitisation were identified in four studies. One of them (Takenaka) could not be properly evaluated because of the lack of information in the experimental conditions used. Therefore, the results of this study could not be considered with full confidence.
Another study identified a surprisingly high rate of positive reactions (13%). This study suffered from major weaknesses that question the reliability of the results reported.
Then, two other studies of relatively good quality identified very low incidence of positive reactions (0.17 and 0.06% among more than 1000 patients tested) although experimental conditions were favouring the occurrence of positive responses (patients suffering from contact dermatitis, many substances tested simultaneously…).
On the other hand, five studies showed no reaction when terpineol multiconstituent was tested. Two of them were performed with too little cohorts of patients (RIFM studies). However, the other ones were of good quality and conducted with a sufficient number of patients. Although the experimental conditions were “pushed” to observe positive responses (contact dermatitis patients in higher ratio than in general population, high concentrations tested…), no reactions were observed in these studies. Lastly, the negative reactions were obtained in three different methodologies (HRIPT, patch test and Human maximisation test) whereas positive responses were observed in patch test methodology only.
The equivocal positive responses observed in humans need to be confronted to the clear negative results observed in some of the human studies and in animal studies.
Therefore, when taking into account all data available in human and in animal studies, terpineol multiconstituent cannot be considered as a skin sensitiser, in a weight of evidence approach.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
